← Leaderboards
Mansoor N Saleh
University Of Alabama At Birmingham
$1,868,012
Attributed
$2,468,010
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $250K · FY2016–25$250K$187.5K$125K$62.5K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,468,010 · 7
By mechanism
P30$928,401 · 1
M01$789,611 · 5
U01$749,998 · 1
Top collaborators
- Ulysses Gregory John Balis3 shared
- Arvind Rao3 shared
- Shahin Sayed3 shared
- Akbar K Waljee3 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- John Franklin Kearney$21,145,276
- Desiree Emma Morgan$860,661
- Jannet Katz$3,241,855
- Jodie Ann Dionne$7,205,056
- Christine A Curcio$7,145,340
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchInnovationFutureFundingHuman SubjectHuman Therapy EvaluationInvestigationCancer CenterNursing ResearchLaboratoriesDesignGrantMeetingsComprehensive Cancer CenterClinical ProtocolsClinical DataCancer Center Support GrantClinical TrialsConduct Clinical TrialsData ManagementExtramural ActivitiesFacultyMonitorProtocols Documentation
Grant awards (25)
Leveraging artificial intelligence/machine learning-based technology to overcome specialized training and technology barriers for the diagnosis and prognostication of colorectal cancer in Africa$249,999
U01 · FY2025 · CA · contact PI
Leveraging artificial intelligence/machine learning-based technology to overcome specialized training and technology barriers for the diagnosis and prognostication of colorectal cancer in Africa$249,999
U01 · FY2024 · CA · contact PI
Leveraging artificial intelligence/machine learning-based technology to overcome specialized training and technology barriers for the diagnosis and prognostication of colorectal cancer in Africa$250,000
U01 · FY2023 · CA · contact PI
Early Phase Clinical Research Support$192,485
P30 · FY2020 · CA · contact PI
Early Phase Clinical Research Support$187,829
P30 · FY2019 · CA · contact PI
Early Phase Clinical Research Support$8,695
P30 · FY2019 · CA · contact PI
Early Phase Clinical Research Support$170,181
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$8,650
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$3,965
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$2,264
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$1,978
P30 · FY2018 · CA · contact PI
Early Phase Clinical Research Support$189,518
P30 · FY2017 · CA · contact PI
Early Phase Clinical Research Support$154,140
P30 · FY2016 · CA · contact PI
Early Phase Clinical Research Support$8,696
P30 · FY2016 · CA · contact PI
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS$175,256
M01 · FY2002 · RR
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA$175,256
M01 · FY2002 · RR
BMS191352 IN ADVANCED CARCINOMA$0
M01 · FY2002 · RR
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS$175,256
M01 · FY2001 · RR
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA$175,256
M01 · FY2001 · RR
BMS191352 IN ADVANCED CARCINOMA$0
M01 · FY2001 · RR
ORAL BCX 34 IN T CELL MALIGANCIES$29,529
M01 · FY2000 · RR
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS$29,529
M01 · FY2000 · RR
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA$29,529
M01 · FY2000 · RR
IDEC-Y902B8 RADIOIMMUNOTHERAPY IN B-CELL NONHODGKINS LYM$0
M01 · FY2000 · RR
BMS191352 IN ADVANCED CARCINOMA$0
M01 · FY2000 · RR